e-Therapeutics plc' Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators  
3/29/2012 7:38:32 AM

OXFORD & NEWCASTLE--(BUSINESS WIRE)--e-Therapeutics plc (AIM:ETX) announces that regulatory agencies in the UK and the US have approved plans for phase I trials of the Company’s anti-cancer drug ETS2101 and that enrolment of patients into trials in these two countries will begin shortly.